Notably, in a mouse ovarian tumor xenograft model, a CAR targeting both human and mouse B7-H4 exhibited efficacy in inducing tumor regression, marking the inaugural instance of CAR T cell therapy targeting B7-H4. This evidence concerns the gene VTCN1 and ovarian neoplasm.